ScholarWorks@SUNGKYUNKWAN UNIVERSITY: SEO, SEONG IL

Detailed Information

SEO, SEONG IL (서성일)

Medicine (Medicine)

Research Area

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Prostate cancer:16||Nephrectomy:15||prostate cancer:14||Prostatectomy:13||renal cell carcinoma:12||Prostatic neoplasms:12||Renal cell carcinoma:11||Robotics:9||Prostatic Neoplasms:7||Magnetic resonance imaging:7||Biopsy:7||Laparoscopy:7||Survival:7||Carcinoma:6||Prognosis:6||Prostate:6||Prostate neoplasms:6||magnetic resonance imaging:5||nephrectomy:5||Partial nephrectomy:5||Kidney:4||bladder cancer:4||Prostatic neoplasm:4||survival:4||prostatectomy:4||Diagnosis:4||prognosis:4||Prostate biopsy:4||Gleason score:4||Urothelial carcinoma:4||metastatic renal cell carcinoma:4||renal cell:4||Biomarkers:3||Upper tract urothelial carcinoma:3||Metastatic renal cell carcinoma:3||kidney neoplasms:3||MRI:3||Hemiablation:3||Kidney neoplasms:3||Outcome:3||Docetaxel:3||Urinary bladder neoplasms:3||Renal Cell:3||Focal therapy:3||Prostatespecific antigen:3||recurrence:3||Radical prostatectomy:3||carcinoma:3||radical prostatectomy:3||Oncologic outcomes:3||prostatic neoplasms:3||tumor microenvironment:2||Operative surgical procedures:2||Renal function:2||machine learning:2||Renal Cell Carcinoma:2||mortality:2||Recurrence:2||Metastasis:2||Repeat biopsy:2||Pathology:2||Risk:2||adjuvant:2||nephroureterectomy:2||Pazopanib:2||Computed tomography:2||biochemical recurrence:2||overall survival:2||Korean:2||Chemotherapy:2||Active surveillance:2||partial nephrectomy:2||Chronic kidney disease:2||Prognosticator:2||prediction:2||predictor:2||Epidemiology:2||prostate health index:2||carcinoma, renal cell:2||Sunitinib:2||Adjuvant chemotherapy:2||Neoplasm:2||prostatespecific antigen:2||prostatespecific antigen density:2||Neoplasm Metastasis:2||prostatic neoplasm:2||Biochemical recurrence:2||curcumin:2||cystectomy:2||Nephroureterectomy:2||diagnosis:2||Targeted biopsy:2||Biweekly:2||Prostatic hyperplasia:2||Transperineal:2||Cancer:2||Transrectal ultrasonography:2||Transrectal ultrasound:2||RCC:2||Treatment outcome:2||Radical Prostatectomy:2||survival prediction:2||glomerular filtration rate:2||hypertrophy:2||Bladder cancer:2||Tyrosine kinase inhibitor:2||Insignificant:2||immunotherapy:2||Nomogram:1||Nomograms:1||Nonclear cell:1||Obesity:1||Observation:1||Oncogene proteins:1||Oncological outcome:1||Organ size:1||Osteosarcoma:1||Outcomes:1||PIRADS:1||PTEN:1||Patient selection:1||Patterns of locoregional recurrence:1||Pentafecta criteria:1||Pentafecta outcome:1||Positive surgical margin:1||Predictive factor:1||Predictive model:1||Predictors:1||Prior biopsynegative patients:1||Prognostic factor:1||Programmed cell death 1 ligand 1:1||Propensity scorematching:1||Prostate Biopsy:1||Prostate Cancer:1||Prostate Imaging Reporting and Data:1||Prostate Imaging Reporting and Data System (PIRADS):1||Prostate ImagingReporting and Data System:1||Prostate cancer database:1||ProstateSpecific Antigen:1||Prostatespecific antigen density (PSAD):1||Proximal ureteral stones:1||Radical cystectomy:1||Radical nephrectomy:1||Radical nephroureterectomy:1||Radical prostatectomy specimen:1||Radiofrequency ablation:1||Radiofrequency catheter ablation:1||Radionuclide imaging:1||Receptor fibroblast growth factor, type 3:1||Registries:1||RelA:1||Renal:1||Renal compensation:1||Renal insufficiency:1||Retrograde intrarenal surgery:1||Retropubic:1||Retrospective:1||Risk Assessment:1||Robotassisted laparoscopic partial nephrectomy:1||Robotic:1||Robotic prostatectomy:1||Robotic surgery:1||Robotic surgical procedures:1||SOX9:1||Salvage:1||Salvage therapy:1||Sarcoma:1||Sarcopenia:1||Seminal vesicle:1||Sequence analysis:1||Smoking:1||Stomach neoplasms:1||Surgery:1||Surgical procedures:1||Survival analysis:1||Synchronous:1||Synchronous metastatic renalcell carcinoma:1||System (PIRADS) score:1||Systematic biopsy:1||Systematic random biopsy:1||Systemic inflammatory response:1||TAZ:1||Targeted Molecular Therapy:1||Technetium Tc 99m Pentetate:1||Terminal differentiation:1||Timetotreatment:1||Tissue residency:1||Transitional cell:1||Transperineal US:1||Transperitoneal laparoscopic ureterolithotomy:1||Treatment Outcome:1||Trend:1||Tumor volu:1||Tumor volume:1||Tumour size:1||UROPDS:1||Ultrasonography:1||Ultrasound:1||Upgrading:1||Upper urinary tract cancer:1||Upper urinary tract urothelial carcinoma:1||Upstaging:1||Ureteroscopic lithotripsy:1||Ureteroscopy:1||Urinary bladder:1||Urinary incontinence:1||Urologic surgical procedures:1||Urothelial cell carcinoma:1||Validation:1||Warm ischaemia:1||Warm ischemia:1||Watchful waiting:1||Whole genome sequencing:1||YAP1:1||abdominal:1||active surveillance:1||adoptive immunotherapy:1||androgen deprivation therapy:1||antitumor immunity:1||aspartate transaminase/alanine transaminase (De Ritis) ratio:1||axitinib:1||biomarker:1||biomarkers:1||biopsy:1||bladder:1||body mass index:1||bone metastasis:1||brain metastasis:1||c:1||cT3:1||cabozantinib:1||cancer:1||caspase6:1||caspase9:1||castrationresistant:1||chronic kidney disease:1||cisplatin:1||clinical decision support system:1||clinical protocols:1||clinically insignificant prostate cancer (CIPC):1||complications:1||cysts:1||deep learning:1||detection:1||diseasefree survival:1||docetaxel:1||drug delivery:1||drug screening:1||early detection of cancer:1||endstage renal disease:1||enhanced permeability retention:1||enzalutamide resistance:1||erythrocyte sedimentation rate:1||expression:1||flow cytometry:1||functional and oncological outcomes:1||gammadelta T cells:1||gastric cancer:1||glioblastoma multiforme:1||gradient boost:1||health screening:1||immune checkpoint inhibitor:1||immune checkpoint inhibitors:1||immunohistochemistry:1||immunosurveillance:1||insignificant:1||intermittent androgen deprivation:1||internet of things:1||kidney:1||laparoscopi:1||laparoscopic surgery:1||large renal tumors:1||late recurrence:1||lifestyle intervention:1||lymphocytes:1||m:1||mediator complex subunit 12:1||metastasectomy:1||molecular features:1||mpMRI:1||multiparametric magnetic resonance imaging:1||muscle invasive bladder cancer:1||mutation:1||mutation analysis:1||nanoparticle:1||natural killer cell activity:1||negative predictive value:1||neoplasm metastasis:1||neoplasm metastasis, local:1||neutrophillymphocyte ratio:1||nomogram:1||nonclear cell:1||obesity:1||oncologic outcome:1||outcome:1||oxidative stress:1||p100:1||p50:1||p52:1||pancreas metastasis:1||patientderived xenograft:1||poly(lacticcoglycolic acid):1||postsurgery metastasis:1||prognostic factors:1||propensity score:1||propensity score matched analysis:1||propensityscore matching analysis:1||prostate health index density:1||prostate imaging and reporting and data system:1||prostate imaging reporting and data system:1||prostate neoplasms:1||prostate specific antigen:1||prostatic neo:1||proteintyrosine kinases:1||proteinuria:1||radical cystectomy:1||radiofrequency ablation:1||radiomics:1||radiotherapy:1||randomized trial:1||responsiveness:1||risk:1||robot assisted gastrectomy:1||robot assisted nephrectomy:1||robotassisted surgery:1||robotic:1||robotic partial nephrectomy:1||robotic surgery:1||robotics:1||safety:1||salvage:1||salvage radiotherapy:1||selection bias:1||smart aftercare:1||staging:1||statistics:1||sunitinib:1||survival outcomes:1||survival rate:1||targeted therapy:1||thrombectomy:1||tomography:1||tomography, xray computed:1||transperineal prostate biopsy:1||transrectal ultrasound:1||treatment outco:1||trend:1||tumor biomarkers:1||tumor microenvironments:1||tumor suppressor:1||tumorinfiltrating:1||tumorinfiltrating lymphocytes:1||tyrosine kinase inhibitor:1||tyrosine kinase inhibitors:1||upper tract urothelial carcinoma:1||upper urinary tract:1||urethral recurrence:1||urothelial carcinoma:1||urothelium cancer:1||watchful waiting:1||근치적 전립샘 절제술:1||레지스트리:1||비뇨기과 수술적 치료:1||예후:1||전립샘 암:1||전립선 적출술:1||.:1||전립선암:1||100:1||ALT:1||ARV7:1||AST:1||Abiraterone acetate:1||Adjuvant:1||Apparent diffusion coefficient:1||Approach:1||Atezolizumab:1||B:1||BNIP3:1||Biochemical Recurrence Prediction:1||Biopsy outcomes:1||Biopsy techniques:1||Biopsynaive patients:1||Bladder cuff method:1||Bladder neoplasm:1||Bladder wall thickening:1||Blood platelets:1||Body Mass Index:1||CD69(+)CD103()CD8(+) T cells:1||Carcinoma, Renal cell:1||Castrateresistant prostate cancer:1||Castrationnaïve prostate cancer:1||Cholesterol:1||Circulating tumor DNA:1||Cisplatin:1||Clinical stage:1||Combination:1||Competing risk analysis:1||Complication:1||Complications:1||Computerized tomography:1||Criteria:1||Cystectomy:1||Cystoscopy:1||Cytology:1||Cytoreductive nephrectomy:1||DNA:1||Database Management Systems:1||Diagnostic imaging:1||Diffusionweighted MRI:1||Dissection:1||Downgrading:1||EGFR:1||ERG:1||ERK:1||Early death:1||Extraskeletal:1||Factor:1||Functional outcomes:1||Gastrectomy:1||Genes:1||Genetic:1||Gleason Score:1||Glomerular filtration rate:1||HIF2 alpha:1||Hemainolevulinate:1||Heng risk criteria:1||High Intensity Focused Ultrasound:1||High grade:1||Highintensity focused ultrasound ablation:1||Histological characteristics:1||Human liver:1||Hypercholesterolemia:1||Hypertrophy:1||IDH1:1||IDH1 codon 132:1||IKK epsilon:1||IMDC poorrisk:1||Incidence:1||Insurance claim review:1||Kidney cancer:1||Kidney function test:1||Kidney neoplasm:1||Kidney transplantation:1||Kidney volume:1||Laparoscopic:1||Laparoscopic partial nephrectomy:1||Laparoscopic prostatectomy:1||Laparoscopic surgery:1||Learning curve:1||Lipid:1||Living donor:1||Locallyadvanced:1||Locoregional recurrence:1||Lower urinary tract symptoms:1||Lymph Node Dissection:1||Lymph Node Metastasis:1||Lymph node excision:1||Lymphocytes:1||Magnetic Resonance Imaging:1||Metachronous:1||Methylation:1||Miles’ operation:1||Minimal invasive surgery:1||Minimally Invasive Surgical Procedures:1||Minimally invasive:1||Minimally invasive surgical procedures:1||Monoclonal antibody:1||Mortality:1||Multidetector computed tomography:1||Mutation:1||NFkappa B:1||Neoadjuvant Therapy:1||Neoplasm metastasis:1||Nephrometry score:1||

STATISTICS: Total View :5,174,328; Today View :0

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE